129 related articles for article (PubMed ID: 11134655)
1. Functional profile of almotriptan in animal models predictive of antimigraine activity.
Gras J; Bou J; Llenas J; Fernández AG; Palacios JM
Eur J Pharmacol; 2000 Dec; 410(1):43-51. PubMed ID: 11134655
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological characterization of almotriptan: an indolic 5-HT receptor agonist for the treatment of migraine.
Bou J; Domènech T; Puig J; Heredia A; Gras J; Fernández-Forner D; Beleta J; Palacios JM
Eur J Pharmacol; 2000 Dec; 410(1):33-41. PubMed ID: 11134654
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular safety profile of almotriptan, a new indolic derivative for the treatment of migraine.
Gras J; Cardelús I; Llenas J; Palacios JM
Eur J Pharmacol; 2000 Dec; 410(1):53-9. PubMed ID: 11134656
[TBL] [Abstract][Full Text] [Related]
4. The in vivo pharmacological profile of eletriptan (UK-116,044): a potent and novel 5-HT(1B/1D) receptor agonist.
Gupta P; Butler P; Shepperson NB; McHarg A
Eur J Pharmacol; 2000 Jun; 398(1):73-81. PubMed ID: 10856450
[TBL] [Abstract][Full Text] [Related]
5. Effects of avitriptan, a new 5-HT 1B/1D receptor agonist, in experimental models predictive of antimigraine activity and coronary side-effect potential.
Saxena PR; De Vries P; Wang W; Heiligers JP; Maassen vandenBrink A; Bax WA; Yocca FD
Naunyn Schmiedebergs Arch Pharmacol; 1997 Feb; 355(2):295-302. PubMed ID: 9050026
[TBL] [Abstract][Full Text] [Related]
6. Vascular effects of the new anti-migraine agent almotriptan on human cranial and peripheral arteries.
Bou J; Gras J; Cortijo J; Morcillo EJ; Llenas J; Palacios JM
Cephalalgia; 2001 Oct; 21(8):804-12. PubMed ID: 11737005
[TBL] [Abstract][Full Text] [Related]
7. BMS-181885, a 5-HT1B/1D receptor ligand, in experimental models predictive of antimigraine activity and coronary side-effect potential.
Saxena PR; De Vries P; Heiligers JP; Bax WA; Maassen VanDenBrink A; Yocca FD
Eur J Pharmacol; 1998 Jun; 351(3):329-39. PubMed ID: 9721025
[TBL] [Abstract][Full Text] [Related]
8. The anti-migraine 5-HT(1B/1D) agonist rizatriptan inhibits neurogenic dural vasodilation in anaesthetized guinea-pigs.
Williamson DJ; Hill RG; Shepheard SL; Hargreaves RJ
Br J Pharmacol; 2001 Aug; 133(7):1029-34. PubMed ID: 11487512
[TBL] [Abstract][Full Text] [Related]
9. Porcine carotid vascular effects of eletriptan (UK-116,044): a new 5-HT1B/1D receptor agonist with anti-migraine activity.
Willems E; De Vries P; Heiligers JP; Saxena PR
Naunyn Schmiedebergs Arch Pharmacol; 1998 Aug; 358(2):212-9. PubMed ID: 9750007
[TBL] [Abstract][Full Text] [Related]
10. The in vivo pharmacological profile of a 5-HT1 receptor agonist, CP-122,288, a selective inhibitor of neurogenic inflammation.
Gupta P; Brown D; Butler P; Ellis P; Grayson KL; Land GC; Macor JE; Robson SF; Wythes MJ; Shepperson NB
Br J Pharmacol; 1995 Nov; 116(5):2385-90. PubMed ID: 8581273
[TBL] [Abstract][Full Text] [Related]
11. The selectivity of MDL 74,721 in models of neurogenic versus vascular components of migraine.
Petty MA; Elands J; Johnson MP; Linnik MD; Hamel E; Moskowitz MA; Lee WS; McCarty DR; Hibert M; Baron BM
Eur J Pharmacol; 1997 Oct; 336(2-3):127-36. PubMed ID: 9384224
[TBL] [Abstract][Full Text] [Related]
12. Spotlight on almotriptan in migraine.
Keam SJ; Goa KL; Figgitt DP
CNS Drugs; 2002; 16(7):501-7. PubMed ID: 12056924
[TBL] [Abstract][Full Text] [Related]
13. Almotriptan: a review of its use in migraine.
Keam SJ; Goa KL; Figgitt DP
Drugs; 2002; 62(2):387-414. PubMed ID: 11817980
[TBL] [Abstract][Full Text] [Related]
14. Cranial vascular effects of zolmitriptan, a centrally active 5-HT1B/1D receptor partial agonist for the acute treatment of migraine.
MacLennan SJ; Cambridge D; Whiting MV; Marston C; Martin GR
Eur J Pharmacol; 1998 Nov; 361(2-3):191-7. PubMed ID: 9865508
[TBL] [Abstract][Full Text] [Related]
15. Effect of antimigraine drugs on dural blood flows and resistances and the responses to trigeminal stimulation.
Lambert G; Michalicek J
Eur J Pharmacol; 1996 Sep; 311(2-3):141-51. PubMed ID: 8891594
[TBL] [Abstract][Full Text] [Related]
16. Almotriptan: pharmacological differences and clinical results.
Pascual J
Curr Med Res Opin; 2001; 17 Suppl 1():s63-7. PubMed ID: 12463281
[TBL] [Abstract][Full Text] [Related]
17. Safety profile of almotriptan, a new antimigraine agent. Effects on central nervous system, renal function and respiratory dynamics.
Gras J; Llupià J; Llenas J; Palacios JM
Arzneimittelforschung; 2001 Sep; 51(9):726-32. PubMed ID: 11642004
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the cardiovascular effects of the novel 5-HT(1B/1D) receptor agonist, SB 209509 (VML251), and sumatriptan in dogs.
Parsons AA; Parker SG; Raval P; Campbell CA; Lewis VA; Griffiths R; Hunter AJ; Hamilton TC; King FD
J Cardiovasc Pharmacol; 1997 Jul; 30(1):136-41. PubMed ID: 9268233
[TBL] [Abstract][Full Text] [Related]
19. Tolerability and efficacy of almotriptan in the long-term treatment of migraine.
Pascual J; Falk R; Docekal R; Prusinski A; Jelencsik J; Cabarrocas X; Segarra X; Luria X; Ferrer P
Eur Neurol; 2001; 45(4):206-13. PubMed ID: 11385257
[TBL] [Abstract][Full Text] [Related]
20. Pre-clinical pharmacology of zolmitriptan (Zomig; formerly 311C90), a centrally and peripherally acting 5HT1B/1D agonist for migraine.
Martin GR
Cephalalgia; 1997 Oct; 17 Suppl 18():4-14. PubMed ID: 9399012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
